Mismatch repair–deficient tumors
The sponsor’s research activity includes dMMR tumors across multiple solid tumor types, with interest in colorectal cancer, oesophageal cancer, gastroesophageal junction cancer, gastric cancer, duodenal and small bowel cancer, endometrial cancer, breast cancer, prostate cancer, and sarcoma.
- Colorectal cancer
- Endometrial cancer
- Sarcoma
Interest in these cancers reflects a broad focus on tumor biomarker-defined oncology and immunotherapy-responsive disease.
Proficient mismatch repair tumors
The sponsor also studies pMMR tumors, particularly gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, esophageal adenocarcinoma, and triple-negative breast cancer.
- Gastric adenocarcinoma
- Esophageal adenocarcinoma
- Triple-negative breast cancer
This area highlights interest in upper gastrointestinal malignancies and aggressive breast cancer subtypes.
Neoadjuvant oncology
Clinical research supported by the sponsor includes pre-operative cancer treatment across tumor baskets, with emphasis on neoadjuvant immuno-oncology in resectable disease.
- Pre-operative treatment strategies
- Resectable solid tumors
- Pathologic response assessment
The therapeutic focus extends to cancers managed with surgery after systemic therapy, especially in gastrointestinal and rectal malignancies.
Immune checkpoint inhibition
The sponsor funds research in immune checkpoint blockade and novel immunotherapy combinations, with attention to treatment approaches designed for solid tumors with distinct molecular profiles.
- Checkpoint inhibitor therapy
- Combination immunotherapy
- Tumor-immune interaction
This includes interest in both mismatch repair–deficient and mismatch repair–proficient cancers.
Gastrointestinal and rectal cancer
Another clear area of interest is gastrointestinal oncology, especially rectal cancer, gastric cancer, esophageal cancer, and gastroesophageal junction cancer.
- Rectal cancer
- Gastric and GEJ cancer
- Esophageal cancer
These studies place the sponsor within a therapeutic landscape centered on digestive system malignancies and solid tumor immunotherapy.
